ClinicalTrials.gg
CompletedNCT04881630P3Updated Nov 18, 2026Results posted

Mobile Contingency Management for Smoking Cessation

An interventional study of Automated Mobile Contingency Management (CM) and Standard Care (SC) in Smoking Cessation, sponsored by University of Oklahoma. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Oklahoma · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
532
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Smoking Cessation by University of Oklahoma — 6 open to participants now, 7 under way, 1 of them phase 3. Smoking Cessation · University of Oklahoma.

Enrollment
3rd of 26
532 · median 81
Started
2022
with 4 others
No phase
17 of 26
3 open now
Registered
15th of 26
by date

Among the 26 studies in Smoking Cessation by University of Oklahoma, this one is the 3rd largest by enrollment, is one of 5 that started in 2022, is one of 17 with no phase, and was the 15th registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

6 of the 26 studies in Smoking Cessation by University of Oklahoma are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Smoking Cessation by University of Oklahoma, or all of them as a file.
02

Study summary

The purpose of the proposed project is to evaluate an automated mobile phone-based CM approach that will allow socioeconomically disadvantaged individuals to remotely benefit from financial incentives for smoking cessation. The investigators have previously combined technologies including 1) portable carbon monoxide monitors that connect with mobile phones to remotely verify smoking abstinence, 2) facial recognition software to confirm participant identity during breath sample submissions, and 3) remote delivery of incentives automatically triggered by biochemical confirmation of self-reported abstinence. This automated CM approach will be evaluated in a randomized controlled trial that includes 532 socioeconomically disadvantaged males and females seeking smoking cessation treatment. Participants will be randomly assigned to either telephone counseling and nicotine replacement therapy (standard care [SC]) or SC plus a mobile financial incentives intervention (CM) for biochemically-confirmed abstinence. Participants will be followed for 26 weeks after a scheduled quit attempt. Biochemically-verified 7-day point prevalence abstinence at 26 weeks post-quit will be the primary outcome variable. Cost-effectiveness will be evaluated to inform policy-related decisions. Potential mobile CM treatment mechanisms, including self-efficacy, motivation, and treatment engagement, will be explored to optimize future versions of the intervention.

Read the detailed description

The primary purpose of the proposed project is to evaluate an automated smartphone-based CM approach that will allow socioeconomically disadvantaged adults to earn financial incentives for smoking cessation without requiring in-person attendance for abstinence verification. The investigators have combined technologies: 1) low-cost carbon monoxide monitors that connect with mobile phones to remotely verify smoking abstinence, 2) facial recognition software to verify the identity of participants while they provide a breath sample, and 3) remote and automated delivery of incentives to a credit card triggered by biochemical confirmation of self-reported smoking abstinence. This CM approach will be evaluated in a randomized controlled trial of 532 socioeconomically disadvantaged males and females seeking smoking cessation treatment. Participants will be randomly assigned to telephone counseling plus nicotine replacement therapy (standard care [SC]) or SC plus a 12-week smartphone-based financial incentives intervention (CM). Participants will be followed for 26 weeks after a scheduled quit attempt, which is 14 weeks after incentives have ended. Cost-effectiveness will be evaluated to inform policy and health care decisions. Potential CM treatment mechanisms, including self-efficacy, motivation, and treatment engagement will be identified to optimize future versions of the intervention. The specific aims are: 1) to evaluate the impact of an automated, mobile phone-based CM approach relative to SC on smoking cessation among socioeconomically disadvantaged adults, 2) to compare the cost-effectiveness of two smoking cessation interventions (CM vs. SC), and 3) to identify mobile CM treatment mechanisms such as motivation to quit, self-efficacy for quitting, and treatment engagement/adherence. The proposed study will evaluate an intervention approach that increases the reach of a potentially effective and cost-effective smoking cessation intervention for socioeconomically disadvantaged smokers. This proposed study is also going to be conducting recruitment nationwide.

03

Conditions studied

  • Smoking Cessation

Browse trials for

Keywords

  • Smoking Cessation
  • Financial Incentives
  • Socioeconomic Status
  • Contingency Management
  • Mobile Health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. report an annual household income of \<200% of the federal poverty threshold (i.e., low-income)
  2. earn a score ≥4 on the REALM indicating >6th grade English literacy level (i.e., a 7th grade reading level is necessary to complete assessments)
  3. are willing to quit smoking 7-14 days after enrollment
  4. are ≥ 18 years of age
  5. currently smoke ≥ 5 cigarettes per day
  6. have a CO level of >6 ppm
  7. are willing to abstain from smoking cannabis and other combustible tobacco products (they raise CO levels and mask cigarette abstinence)
  8. have no for NRT
  9. Provide a copy/photo of driver's license or other documentation as proof of identity and U.S. residence

Exclusion criteria

Exclusion Criteria

1) do not meet the specified inclusion criteria

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
532 participants (actual)

Study arms

  • Active comparator
    Standard Care (SC)

    Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.

    Other: Standard Care (SC)

  • Experimental
    Contingency Management (CM)

    CM participants will receive standard care in addition to small financial incentives for biochemically-verified abstinence.

    Behavioral: Automated Mobile Contingency Management (CM) · Other: Standard Care (SC)

Interventions

  • BehavioralAutomated Mobile Contingency Management (CM)

    Financial incentives contingent upon smoking abstinence

  • OtherStandard Care (SC)

    Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges)

06

What researchers measure

Primary outcomes

  1. Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)

    Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 26 weeks post-quit.

    Time frame: 26 weeks post-quit-date

Secondary outcomes

  1. Cost-effectiveness

    The incremental cost effectiveness ratio (ICER) calculated as the difference in mean costs between the new (CM) and standard treatment (SC) divided by the difference in mean effectiveness between the two, estimates additional resources needed to achieve an increase of one unit of effectiveness. The ICER is then compared with published threshold values for cost-effective interventions. The cost model will include all necessary personnel, hardware, and material costs.

    Time frame: 26 weeks post-quit-date

  2. Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)

    Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 12 weeks post-quit-date.

    Time frame: 12 week post-quit-date

  3. Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)

    Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 8 weeks post-quit-date.

    Time frame: 8 weeks post-quit-date

  4. Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)

    Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 4 weeks post-quit-date.

    Time frame: 4 weeks post-quit-date

  5. Carbon Monoxide-Verified Smoking Abstinence (Past 30 Days)

    Number of participants with carbon monoxide-verified 30-day point prevalence abstinence at 26 weeks post-quit-date.

    Time frame: 26 weeks post-quit-date

07

Results

Posted Nov 18, 2026

Participant flow

Participant flow — Overall Study
MilestoneStandard Care (SC)Contingency Management (CM)
Started267265
Completed220217
Not completed4748

Outcome measures

PrimaryCarbon Monoxide-Verified Smoking Abstinence (Past 7 Days)

Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 26 weeks post-quit.

Time frame:
26 weeks post-quit-date
Reported as:
Count of participants · Participants
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
ParticipantsStandard Care (SC)Contingency Management (CM)
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)3550
SecondaryCost-effectiveness

The incremental cost effectiveness ratio (ICER) calculated as the difference in mean costs between the new (CM) and standard treatment (SC) divided by the difference in mean effectiveness between the two, estimates additional resources needed to achieve an increase of one unit of effectiveness. The ICER is then compared with published threshold values for cost-effective interventions. The cost model will include all necessary personnel, hardware, and material costs.

Time frame:
26 weeks post-quit-date

Results for this outcome have not been posted.

SecondaryCarbon Monoxide-Verified Smoking Abstinence (Past 7 Days)

Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 12 weeks post-quit-date.

Time frame:
12 week post-quit-date
Reported as:
Count of participants · Participants
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
ParticipantsStandard Care (SC)Contingency Management (CM)
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)3955
SecondaryCarbon Monoxide-Verified Smoking Abstinence (Past 7 Days)

Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 8 weeks post-quit-date.

Time frame:
8 weeks post-quit-date
Reported as:
Count of participants · Participants
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
ParticipantsStandard Care (SC)Contingency Management (CM)
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)3564
SecondaryCarbon Monoxide-Verified Smoking Abstinence (Past 7 Days)

Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 4 weeks post-quit-date.

Time frame:
4 weeks post-quit-date
Reported as:
Count of participants · Participants
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
ParticipantsStandard Care (SC)Contingency Management (CM)
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)5471
SecondaryCarbon Monoxide-Verified Smoking Abstinence (Past 30 Days)

Number of participants with carbon monoxide-verified 30-day point prevalence abstinence at 26 weeks post-quit-date.

Time frame:
26 weeks post-quit-date
Reported as:
Count of participants · Participants
Carbon Monoxide-Verified Smoking Abstinence (Past 30 Days)
ParticipantsStandard Care (SC)Contingency Management (CM)
Carbon Monoxide-Verified Smoking Abstinence (Past 30 Days)3246

Adverse events

Collected over 27 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard Care (SC)0/267 (0%)0/267 (0%)8/267 (3%)
Contingency Management (CM)0/265 (0%)0/265 (0%)6/265 (2.3%)
Most frequent other events
Most frequent other events
EventStandard Care (SC)Contingency Management (CM)
Possible NRT side effectsGeneral disorders3/2672/265
Sleep DisturbanceGeneral disorders1/2671/265
Payment ErrorProduct Issues1/2671/265
Breath Monitor Device ProblemsProduct Issues1/2671/265
Elevated PHQ score (depression)Psychiatric disorders0/2671/265
Elevated Blood PressureCardiac disorders1/2670/265
General Study ProcessesGeneral disorders1/2670/265

Baseline characteristics

Age, Continuous
Age, Continuous(years)Standard Care (SC)Contingency Management (CM)Total
Mean53.69 ± 11.4553.11 ± 12.2353.40 ± 11.83
Sex: Female, Male
Sex: Female, Male(Participants)Standard Care (SC)Contingency Management (CM)Total
Female186183369
Male8182163
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Standard Care (SC)Contingency Management (CM)Total
Hispanic or Latino211637
Not Hispanic or Latino246249495
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Standard Care (SC)Contingency Management (CM)Total
American Indian or Alaska Native9716
Asian527
Native Hawaiian or Other Pacific Islander112
Black or African American5463117
White177180357
More than one race211233
Unknown or Not Reported000
Annual Household Income
Annual Household Income(Participants)Standard Care (SC)Contingency Management (CM)Total
<$21,000162155317
>=$22,000105110215
Cigarettes Smoked Per Day (pre-quit)
Cigarettes Smoked Per Day (pre-quit)(Cigarettes per day)Standard Care (SC)Contingency Management (CM)Total
Mean17.61 ± 8.7817.51 ± 8.7717.56 ± 8.77
08

Study locations

1 site
  • TSET Health Promotion Research Center
    Oklahoma City, OK, Oklahoma 73104, United States
09

References and documents

Publications

  • Kendzor DE, Businelle MS, Vidrine DJ, Frank-Pearce SG, Shih YT, Dallery J, Alexander AC, Boozary LK, Waring JJC, Ehlke SJ. Mobile contingency management for smoking cessation among socioeconomically disadvantaged adults: Protocol for a randomized trial. Contemp Clin Trials. 2022 Mar;114:106701. doi: 10.1016/j.cct.2022.106701. Epub 2022 Jan 31. PubMed 35114409 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified data will be made available to investigators upon request, after publication of the primary study findings, and with a data-sharing agreement that specifies the investigator(s) will 1) use the data only for research purposes and not to identify any individual participant, 2) store the data on a secure device (e.g., encrypted, password-protected), and 3) destroy or return the data after completion of the analyses.

Supporting information: Study protocol, Informed consent form

Time frame: De-identified data will be made available to investigators upon request after publication of the primary study findings.

Access criteria: Data sharing agreement

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Sep 2025, 34 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's 34 months is above that.

Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2021
First posted
May 11, 2021
StartActual
Nov 8, 2022
Primary completionActual
Sep 21, 2025
CompletionActual
Sep 21, 2025
Results first posted
Nov 18, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 18, 2026
Sites
1 site added, 1 site removed
Show site
  • TSET Health Promotion Research Center · Oklahoma City, OK, United States
Show 1 removed
  • TSET Health Promotion Research Center · Oklahoma City, United States
Nov 18, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedCarbon monoxideMonoxide-verified smoking abstinenceVerified Smoking Abstinence (Past 7 Days)Time frame: 26 weeks post-quit-date
Nov 18, 2026
Documents
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedCarbon monoxideMonoxide-verified smoking abstinenceVerified Smoking Abstinence (Past 7 Days)Time frame: 12 week post-quit-date
  • EditedCarbon monoxideMonoxide-verified smoking abstinenceVerified Smoking Abstinence (Past 7 Days)Time frame: 8 weeks post-quit-date
  • EditedCarbon monoxideMonoxide-verified smoking abstinenceVerified Smoking Abstinence (Past 7 Days)Time frame: 4 weeks post-quit-date
  • EditedCarbon monoxideMonoxide-verified smoking abstinenceVerified Smoking Abstinence (Past 30 Days)Time frame: 26 weeks post-quit-date
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • TSET Health Promotion Research Center · Oklahoma City, OK, United States
    Show 1 removed
    • TSET Health Promotion Research Center · Oklahoma City, United States
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedCarbon monoxideMonoxide-verified smoking abstinenceVerified Smoking Abstinence (Past 7 Days)Time frame: 26 weeks post-quit-date
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedCarbon monoxideMonoxide-verified smoking abstinenceVerified Smoking Abstinence (Past 7 Days)Time frame: 12 week post-quit-date
    • EditedCarbon monoxideMonoxide-verified smoking abstinenceVerified Smoking Abstinence (Past 7 Days)Time frame: 8 weeks post-quit-date
    • EditedCarbon monoxideMonoxide-verified smoking abstinenceVerified Smoking Abstinence (Past 7 Days)Time frame: 4 weeks post-quit-date
    • EditedCarbon monoxideMonoxide-verified smoking abstinenceVerified Smoking Abstinence (Past 30 Days)Time frame: 26 weeks post-quit-date
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04881630
Responsible party
Sponsor
First posted
May 11, 2021
Start date
Nov 8, 2022
Primary completion
Sep 21, 2025
Completion
Sep 21, 2025
Results posted
Nov 18, 2026
Last update
Nov 18, 2026

Study contacts

Darla E. Kendzor, PhD
principal investigator · University of Oklahoma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion